Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 15, 2009. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share purchase transactions:
- Mr. A P Witty: Purchased 8,718 Ordinary shares at £10.57 per share and 676 Ordinary shares at £10.56 per share.
- Mr. S M Bicknell: Purchased 675 Ordinary shares at £10.58 per share.
Material Changes
The filing reports changes in share ownership interests for two directors. No material changes to the company's financial position or operations are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of director share transactions under Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares purchased by directors against the company's insider trading policy.
- Confirm the share price range (£10.56–£10.58) against the market price on May 15, 2009.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.